CELL INTELLIGENCE · 肿瘤细胞治疗研究

在接受 B 细胞成熟抗原靶向 CAR-T 细胞治疗的多发性骨髓瘤患者中平衡疗效与安全性

Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.

CAR-T 细胞基因治疗的综合评价：追溯其革命性临床突破与迈向下一代工程的进展

A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engin

基于这些进展，我们假设 CAR-T 疗法正经历从单靶点细胞毒性向多功能、可编程框架的范式转变，该框架能够克服耐药性、增强安全性，并实现实体瘤的有效渗透。

多发性骨髓瘤的治疗前沿：临床试验新兴格局分析

Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials.

多发性骨髓瘤临床试验的增加凸显了向生物治疗的转变，尤其是免疫治疗和 CAR-T 等基因治疗。

NOG 小鼠中 BCMA-CAR 治疗多发性骨髓瘤可阻止贫血与骨病变进展

BCMA-CAR Therapy for Multiple Myeloma in NOG Mice Prevents the Progression of Anemia and Bone Lesions.

idecabtagene vicleucel（ide-cel）用于治疗三类药物暴露的复发/难治性多发性骨髓瘤

Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma.

多发性骨髓瘤中的 CAR-T 疗法：释放未来

CAR T therapies in multiple myeloma: unleashing the future.

一种替代性全人源抗 BCMA CAR-T 对既往接受过抗 BCMA CAR-T 的复发/难治性多发性骨髓瘤显示缓解

An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.

CRISPR-Cas9 系统：β 血红蛋白病、血液系统恶性肿瘤与血友病基因治疗的新颖而前景广阔的时代

CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia.

已上市 CAR-T 细胞（CAR-T 细胞）治疗的实施与运营管理：GoCART Coalition 药师工作组的指南

Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmac

美国 CAR-T 细胞疗法 ciltacabtagene autoleucel 与 idecabtagene vicleucel 治疗复发/难治性多发性骨髓瘤成人患者的经济负担

The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or

本研究发现，用于 rrMM 的 CAR-T 细胞基因疗法 ciltacabtagene autoleucel 和 idecabtagene vicleucel 对美国医疗支付方构成了显著的经济负担。